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Purpose or Objective: Hypopharyngeal squamous cell 
carcinoma (HPSCC) is rarely diagnosed in early stage due to 
the nonspecific nature of early symptoms. Since its rarity, 
few reports regarding the treatment outcome are available 
and the most optimal treatment for early stage HPSCC has 
not yet been clarified. We assessed patterns of failure and 
factors that influence failures. 
 
Material and Methods:  total of 36 patients with 
pathologically confirmed stage I (n = 10) and II (n = 26) 
treated between January 1992 and March 2014 were 
retrospectively reviewed. Ten patients (28%) received 
definitive RT delivered with a median fraction dose 2.1 
Gy(range, 1.8‒2.3 Gy) to median total dose 69.1 Gy (range, 
60.8‒70.2 Gy) (R group). Nineteen patients (53%) underwent 
surgery only (S group). Seven patients (19%) treated with 
surgery followed by postoperative RT with a median fraction 
dose of 1.8 Gy (range 1.8‒2.3 Gy) to median total dose was 
63.0 Gy (range, 54.0‒66.6 Gy) (PORT group). Twenty-six 
patients received surgery included mass excision/partial 
pharyngectomy (n = 20), total laryngectomy with partial 
pharyngectomy (n = 4), and total pharyngolaryngectomy (n = 
2). Additionally, 4 of S group had no elective neck node 
dissection, seven patients had ipsilateral and eight patients 
had bilateral dissection. All of 10 patients in the R group and 
in the PORT group received elective bilateral neck 
irradiation. 
 
Results: At a median follow-up of 48 months, the 5-year 
locoregional control rate (LRC) was 65%. Of the 36 patients, 5 
patients had local failure (LF), one had regional failure (RF), 
three had combined locoregional failure (LRF) and two had 
distant failure. No differences were observed in the 5-year 
LRC among three groups (R, S, and PORT = 67%, 52%, and 
100%;, P = 0.17). In the RT group, 3 patients experienced LF 
without RF. In the S group, 7 patients experienced LRF; 2 LF, 
1 RF, and 3 combined LRF. There was no LRF in the PORT 
group though resection margin status of patients in the PORT 
group were more risky than in the S group (Close/Positive 
margin 85% vs. 32%; P = 0.03) Patients with pyriform sinus 
apex extension showed a trend toward lower LRC (38% vs. 
76%; P = 0.09). Patients with bilaterally treated neck 
(Treated neck group) showed lower trend of RF rate (4% vs. 
27%; P= 0.08). Of the 10 patients who experienced LRF, 9 
patients were successfully salvaged and 5-yr LRC after 
salvage treatment was 80%. Although late events of 
gastrostomy or tracheostomy were observed in 8 patients; 2 
patients in the untreated or ipsilaterally treated neck group, 
6 patients in the treated neck group (18% vs. 24%; P = 0.70) 
 
Conclusion: Multimodal approach achieved favorable 
locoregional disease control despite of the risk factor. There 
is no difference in LRC between R group and S group. 
Prophylactic treatment of lymph nodes in the neck improves 
regional control in selected early HPSCC. Future research in 
the significance of tumor extension and elective neck 
treatment will be necessary to define the optimal treatment. 
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Purpose or Objective: We investigated 18F-
fluorodeoxyglucose positron emission tomography (PET)-
derived parameters as prognostic indices for disease 
progression and survival in locally advanced nasopharyngeal 
carcinoma (NPC) and the effect of high-dose radiotherapy for 
a subpopulation with PET-based poor prognoses. 
 
Material and Methods: Ninety-seven stage III and IVa–b NPC 
patients who underwent definitive treatment and PET were 
reviewed. For each primary, nodal and whole tumor, 
maximum standardized uptake value, metabolic tumor 
volume, and total lesion glycolysis (TLG) were evaluated. The 
primary endpoint was progression-free survival (PFS). PFS was 
calculated from the treatment start date to the date of 
disease progression, relapse, death from any cause, or last 
contact. Overall actuarial survival (OS) was calculated from 
the treatment start date to the date of death or the last 
follow-up. PFS and OS were calculated using the Kaplan–
Meier method. The Contal and O’Quigley method was 
performed to determine the cut-off value for the most useful 
PET parameter from the C-index and iAUC to allow for 
dichotomization in an objective manner. 
 
Results: The median follow-up duration among surviving 
patients was 47 months (range, 8–127). Based on the C-index 
(0.666) and iAUC (0.669), the whole tumor TLG was the most 
useful predictor for progression-free survival (PFS); the whole 
tumor TLG cut-off value showing the best predictive 
performance was 322.7. The low-whole tumor TLG group 
showed significantly higher 5-year PFS (77.0% vs. 43.0%, P < 
0.001), overall survival (OS) (85.7% vs. 54.0%, P = 0.003), 
loco-regional failure free survival (77.0% vs. 49.1%, P = 0.001) 
and distant-failure free survival (81.6% vs. 60.3%, P = 0.012) 
rates than the high-whole tumor TLG group. The whole tumor 
TLG was one of the significant prognostic factors for PFS (HR, 
0.29; 95% CI, 0.13–0.64; P = 0.002) and OS (HR, 0.29; 95% CI, 
0.11–0.79; P = 0.02) in multivariate analysis. Patients with 
low-whole tumor TLG showed higher 5-year PFS in the 
subgroup for only patients receiving intensity-modulated 
radiotherapy (77.4% vs. 53.0%, P = 0.01). In the subgroup of 
patients with high-whole tumor TLG, patients receiving an 
EQD2 ≥70 Gy showed significantly greater complete remission 
(71.4% vs. 33.3%, P = 0.03) and higher 5-year OS rates (74.7% 
vs. 19.6%, P = 0.02). 
 
Conclusion: Our findings demonstrated that the whole tumor 
TLG could be an independent prognostic factor and high-dose 
radiotherapy could improve outcomes for NPC showing high 
whole tumor TLG. 
 
EP-1074  
Circulating cell free DNA: dynamics in patients with head 
and neck cancer during radiochemotherapy 
K. Zwirner
1Department of Radiation Oncology, Medical Faculty and 
University Hospital- Eberhard Karls University Tübingen, 
Tübingen, Germany 
1, F. Hilke2, C. Schroeder2, O. Rieß2, D. Zips1, S. 
Welz1 
2Institute of Medical Genetics and Applied Genomics, Medical 
Faculty and University Hospital- Eberhard Karls University 
Tübingen, Tübingen, Germany 
 
Purpose or Objective: The analysis of circulating cell free 
DNA (cfDNA) in plasma samples of cancer patients (‘liquid 
biopsy’) is an upcoming option in detecting cancer 
characteristics, dynamics, prognosis and recurrence. 
Combining quantitative analysis, genetic information and 
clinical data appears as a promising tool in personalised 
medicine. 
 
Material and Methods: In a prospective pilot study a total of 
9 patients with head and neck cancer (median age 64.7 
years) receiving primary radiochemotherapy were analysed 
regarding cfDNA dynamics and genetic alterations. Blood 
samples were taken prior to therapy, during therapy (week 
1,4,6) and 6 weeks after end of treatment. 
 
